DBVT Stock Analysis: Buy, Sell, or Hold?
DBVT - DBV Technologies S.A.
$13.50
-0.31 (-2.24%)
▼
5d:
-0.95%
30d:
-14.18%
90d:
-35.71%
BUY
MODERATE Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Oct 28, 2026
Get Alerted When DBVT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: DBVT shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: DBVT shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: DBVT is currently trading at $13.50, which is considered oversold relative to its 30-day fair value range of $13.98 to $16.31.
Technical Outlook: Technically, DBVT is in a strong downtrend. Immediate support is located at $13.00, while resistance sits at $14.61.
Market Sentiment: DBVT has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (15th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $41.05 (+204.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, DBVT is in a strong downtrend. Immediate support is located at $13.00, while resistance sits at $14.61.
Market Sentiment: DBVT has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (15th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $41.05 (+204.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$13.98 -
$16.31
Company Quality Score
41/100
(HOLD)
Options IV Signal
15th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
66.7%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 15th percentile)
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 204.1% below Wall St target ($41.05)
Trading Range Analysis
30-Day Trading Range
$13.98 -
$16.31
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$1.66
(12.3%)
Support & Resistance Levels
Support Level
$13.00
Resistance Level
$14.61
Current Trend
Strong Downtrend
Technical data as of
Jul 31, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-29.33
Wall Street Target
$41.05
(+204.1%)
Revenue Growth (YoY)
-53.3%
Share & Embed Analysis
Last updated: August 03, 2026 12:13 AM ET
Data refreshes hourly during market hours. Next update: 1:13 AM
Data refreshes hourly during market hours. Next update: 1:13 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is DBVT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 49 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1080 | 57 HOLD |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$52 | 54 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$127 | 59 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |